>
HOOKIPA Pharma Inc logo

HOOK - HOOKIPA Pharma Inc Share Price

$12.39 -1.3  -9.6%

Last Trade - 9:00pm

Sector
Healthcare
Size
Small Cap
Market Cap £297.9m
Enterprise Value £197.4m
Revenue £14.3m
Position in Universe 3765th / 6825
Bullish
Bearish
Unlock HOOK Revenue
Momentum
Relative Strength (%)
1m +10.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -11.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 7.63 11.9 19.6 18.4 19.0
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, HookipaPharma Inc revenues increased 64% to $19.6M. Net lossincreased 2% to $44.1M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsResearch and development - Balancing val increase of 10% to$47.2M (expense), Stock-based Compensation in R&D increasefrom $2M to $5.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for HOOK
Graphical History

Revenue

HOOK Revenue Unlock HOOK Revenue

Net Income

HOOK Net Income Unlock HOOK Revenue

Normalised EPS

HOOK Normalised EPS Unlock HOOK Revenue

PE Ratio Range

HOOK PE Ratio Range Unlock HOOK Revenue

Dividend Yield Range

HOOK Dividend Yield Range Unlock HOOK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
HOOK EPS Forecasts Unlock HOOK Revenue
Profile Summary

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is developing products to prevent and cure infectious diseases and cancer. The Company's infectious and oncology product candidates HB-101, HB-201 and HB-202. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company offers VaxWave technology, which is designed to induce a robust CD8+ T cell and pathogen neutralizing response to fight disease. VaxWave technology supports the benefits of our arenavirus platform approach.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated February 15, 2017
Public Since April 18, 2019
No. of Shareholders: 11
No. of Employees: 109
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 29,789,344
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HOOK Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for HOOK
Upcoming Events for HOOK
Frequently Asked Questions for HOOKIPA Pharma Inc
What is the HOOKIPA Pharma Inc share price?

As of 9:00pm, shares in HOOKIPA Pharma Inc are trading at $12.39, giving the company a market capitalisation of £297.9m. This share price information is delayed by 15 minutes.

How has the HOOKIPA Pharma Inc share price performed this year?

Shares in HOOKIPA Pharma Inc are currently trading at $12.39 and the price has moved by 71.8% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the HOOKIPA Pharma Inc price has moved by 15.8% over the past year.

What are the analyst and broker recommendations for HOOKIPA Pharma Inc?

Of the analysts with advisory recommendations for HOOKIPA Pharma Inc, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for HOOKIPA Pharma Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will HOOKIPA Pharma Inc next release its financial results?

HOOKIPA Pharma Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the HOOKIPA Pharma Inc dividend yield?

HOOKIPA Pharma Inc does not currently pay a dividend.

Does HOOKIPA Pharma Inc pay a dividend?

HOOKIPA Pharma Inc does not currently pay a dividend.

When does HOOKIPA Pharma Inc next pay dividends?

HOOKIPA Pharma Inc does not currently pay a dividend.

How do I buy HOOKIPA Pharma Inc shares?

To buy shares in HOOKIPA Pharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of HOOKIPA Pharma Inc?

Shares in HOOKIPA Pharma Inc are currently trading at $12.39, giving the company a market capitalisation of £297.9m.

Where are HOOKIPA Pharma Inc shares listed? Where are HOOKIPA Pharma Inc shares listed?

Here are the trading details for HOOKIPA Pharma Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: HOOK
What kind of share is HOOKIPA Pharma Inc?

Based on an overall assessment of its quality, value and momentum, HOOKIPA Pharma Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a HOOKIPA Pharma Inc share price forecast 2021?

Shares in HOOKIPA Pharma Inc are currently priced at $12.39. At that level they are trading at 60.47% discount to the analyst consensus target price of 0.00.

Analysts covering HOOKIPA Pharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.281 for the next financial year.

How can I tell whether the HOOKIPA Pharma Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HOOKIPA Pharma Inc. Over the past six months, the relative strength of its shares against the market has been 25.54%. At the current price of $12.39, shares in HOOKIPA Pharma Inc are trading at 23.6% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the HOOKIPA Pharma Inc PE Ratio?

We were not able to find PE ratio data for HOOKIPA Pharma Inc.

Who are the key directors of HOOKIPA Pharma Inc?

HOOKIPA Pharma Inc's management team is headed by:

Joern Aldag - CEO
Reinhard Kandera - CFO
Igor Matushansky - OTH
Klaus Orlinger - EVP
Roman Necina - CTO
Jan van de Winkel - CHM
David Kaufman - IND
Michael Kelly - IND
Julie O Neill - IND
Christoph Lengauer - IND
Who are the major shareholders of HOOKIPA Pharma Inc?

Here are the top five shareholders of HOOKIPA Pharma Inc based on the size of their shareholding:

Sofinnova Partners Venture Capital
Percentage owned: 13.37% (3.47m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 9.83% (2.55m shares)
Forbion Capital Partners Venture Capital
Percentage owned: 8.25% (2.14m shares)
Gilead Sciences Inc Corporation
Percentage owned: 8.06% (2.09m shares)
Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 7.1% (1.84m shares)
Similar to HOOK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.